JP2023503601A5 - - Google Patents

Info

Publication number
JP2023503601A5
JP2023503601A5 JP2022530210A JP2022530210A JP2023503601A5 JP 2023503601 A5 JP2023503601 A5 JP 2023503601A5 JP 2022530210 A JP2022530210 A JP 2022530210A JP 2022530210 A JP2022530210 A JP 2022530210A JP 2023503601 A5 JP2023503601 A5 JP 2023503601A5
Authority
JP
Japan
Prior art keywords
alkyl
dimethylocta
dien
dihydroxy
sulfonyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022530210A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023503601A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/CA2020/051607 external-priority patent/WO2021102567A1/en
Publication of JP2023503601A publication Critical patent/JP2023503601A/ja
Publication of JP2023503601A5 publication Critical patent/JP2023503601A5/ja
Pending legal-status Critical Current

Links

JP2022530210A 2019-11-26 2020-11-25 カンナビゲロール誘導体、およびカンナビノイド受容体モジュレーターとしてのその使用 Pending JP2023503601A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962940545P 2019-11-26 2019-11-26
US62/940,545 2019-11-26
US202063110479P 2020-11-06 2020-11-06
US63/110,479 2020-11-06
PCT/CA2020/051607 WO2021102567A1 (en) 2019-11-26 2020-11-25 Cannabigerol derivatives and use thereof as cannabinoid receptor modulators

Publications (2)

Publication Number Publication Date
JP2023503601A JP2023503601A (ja) 2023-01-31
JP2023503601A5 true JP2023503601A5 (cg-RX-API-DMAC7.html) 2023-11-22

Family

ID=76128559

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022530210A Pending JP2023503601A (ja) 2019-11-26 2020-11-25 カンナビゲロール誘導体、およびカンナビノイド受容体モジュレーターとしてのその使用

Country Status (4)

Country Link
US (1) US12084407B2 (cg-RX-API-DMAC7.html)
EP (1) EP4065554A4 (cg-RX-API-DMAC7.html)
JP (1) JP2023503601A (cg-RX-API-DMAC7.html)
WO (1) WO2021102567A1 (cg-RX-API-DMAC7.html)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3994114A4 (en) 2019-07-04 2023-08-16 Canopy Growth Corporation CANNABINOID DERIVATIVES
WO2021007663A1 (en) 2019-07-12 2021-01-21 Canopy Growth Corporation Cannabinoid derivatives
EP3997098A4 (en) 2019-07-12 2023-10-11 Canopy Growth Corporation Cannabinoid derivatives
WO2021007661A1 (en) 2019-07-12 2021-01-21 Canopy Growth Corporation Cannabinoid derivatives
JP2022551066A (ja) 2019-10-02 2022-12-07 キャノピー グロウス コーポレイション カンナビノイド誘導体
US12617765B2 (en) 2019-12-09 2026-05-05 Canopy Growth Corporation Cannabinoid derivatives
IL312785B2 (en) 2020-05-19 2026-06-01 Cybin Irl Ltd Deuterated tryptamine derivatives and methods of use
WO2022105810A1 (zh) * 2020-11-17 2022-05-27 中国科学院上海药物研究所 一类间苯二酚化合物及其制备方法以及在神经系统疾病中的应用

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8481085B2 (en) * 2006-06-15 2013-07-09 Gw Pharma Limited Pharmaceutical compositions comprising cannabigerol
DK2913321T3 (da) * 2014-02-27 2021-10-25 Emerald Health Pharmaceuticals Inc Hidtil ukendte cannabigerolderivater
EP3994114A4 (en) 2019-07-04 2023-08-16 Canopy Growth Corporation CANNABINOID DERIVATIVES
US20220242844A1 (en) 2019-07-04 2022-08-04 Canopy Growth Corporation Cannabinoid derivatives
EP3997098A4 (en) 2019-07-12 2023-10-11 Canopy Growth Corporation Cannabinoid derivatives
WO2021007663A1 (en) 2019-07-12 2021-01-21 Canopy Growth Corporation Cannabinoid derivatives
WO2021007659A1 (en) 2019-07-12 2021-01-21 Canopy Growth Corporation Cannabinoid derivatives
WO2021007660A1 (en) 2019-07-12 2021-01-21 Canopy Growth Corporation Cannabinoid derivatives
WO2021007661A1 (en) 2019-07-12 2021-01-21 Canopy Growth Corporation Cannabinoid derivatives
WO2021062557A1 (en) 2019-10-02 2021-04-08 Canopy Growth Corporation Cannabinoid derivatives
JP2022551066A (ja) 2019-10-02 2022-12-07 キャノピー グロウス コーポレイション カンナビノイド誘導体
JP2023503330A (ja) 2019-11-26 2023-01-27 キャノピー グロウス コーポレイション カンナビノイド誘導体
US20230122510A1 (en) 2019-11-26 2023-04-20 Canopy Growth Corporation Cannabinoid derivatives
US20230059582A1 (en) 2019-12-09 2023-02-23 Canopy Growth Corporation Cannabinoid derivatives
US12617765B2 (en) 2019-12-09 2026-05-05 Canopy Growth Corporation Cannabinoid derivatives

Similar Documents

Publication Publication Date Title
JP2022540434A5 (cg-RX-API-DMAC7.html)
JP2022539400A5 (cg-RX-API-DMAC7.html)
JP2023503330A5 (cg-RX-API-DMAC7.html)
JP2022551066A5 (cg-RX-API-DMAC7.html)
JP2023505513A5 (cg-RX-API-DMAC7.html)
JP2023503331A5 (cg-RX-API-DMAC7.html)
JP2022540432A5 (cg-RX-API-DMAC7.html)
ES2618812T3 (es) Antagonistas del receptor mineralocorticoide
JP2022540586A5 (cg-RX-API-DMAC7.html)
US7812040B2 (en) Histamine-3 receptor antagonists
JP6466348B2 (ja) スルファモイル−アリールアミドおよびb型肝炎を処置するための医薬品としてのその使用
AU2010242496B2 (en) Processes for the preparation of Rivaroxaban and intermediates thereof
ES2532357T3 (es) Derivados de sulfonamida como inhibidores de Nav1.7 para el tratamiento del dolor
JP2013538198A5 (cg-RX-API-DMAC7.html)
NL1026438C2 (nl) Nieuwe verbindingen.
JP5342451B2 (ja) Pde4阻害剤として有用な置換アセトフェノン
IL287159B2 (en) Small molecules agonists for FXR (farnesoid X receptor) and method for their preparation and use
JP2022539401A5 (cg-RX-API-DMAC7.html)
AU2010362639B2 (en) Processes for the preparation of Rivaroxaban and intermediates thereof
JP2010516635A5 (cg-RX-API-DMAC7.html)
JP2013513615A (ja) 脂肪酸アミドヒドロラーゼのアゾ環状阻害薬
WO2008150492A1 (en) Tricyclic inhibitors of fatty acid amide hydrolase
JP2007507542A5 (cg-RX-API-DMAC7.html)
CN101959855A (zh) 氮杂环丁烷衍生化合物、其制备方法和其治疗用途
KR20070050475A (ko) 신규 환상 아미노 안식향산 유도체